Tranexamic Acid 500mg Tablets (Epistaxis)

This page is an ORAL 500 mg tablet page for EPISTAXIS. §4.1 of this product, verbatim, licenses 'Short-term use for haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. Local fibrinolysis as occurs in the following conditions: … c) Epistaxis'. §4.2 then gives an epistaxis-specific oral regimen, verbatim: 'c) Epistaxis: Where recurrent bleeding is anticipated oral therapy (2 tablets three times daily) should be administered for 7 days.' The tablet strength is the product's own — 'Tranexamic Acid 500 mg Tablets'. Both figures in the dose line ('2 … tablets', '500 mg') and the duration ('7 days') are printed in the source; no total in grams is stated for this indication, so none is written here. || NO MAXIMUM DOSE IS PUBLISHED FOR THIS INDICATION, AND THAT IS DELIBERATE. §4.2 prints exactly one ceiling — 'A total dose of 4g daily (8 tablets) should not be exceeded' — and that sentence sits inside the MENORRHAGIA paragraph, not the epistaxis paragraph. Importing it here would be a cross-indication ceiling, so maxDose is left unset. || PAEDIATRIC BLOCK DELIBERATELY DROPPED (this is the change that makes the page publishable). §4.2 does carry a children's figure, verbatim: 'Children's dosage: This should be calculated according to body weight at 25 mg /kg per dose. However, data on efficacy, posology and safety for these indications are limited.' It is not published because (a) no frequency is stated in the children's paragraph, and (b) at 25 mg/kg per dose any child at or above about adult weight would be shown a per-dose amount exceeding the adult epistaxis regimen on the same page, with no age or weight bound in the label to stop it. Paediatric epistaxis dosing must be checked against a children's formulary. || CONTEXT FROM THE SAME SECTION: epistaxis is item (c) under '1. Local fibrinolysis', whose general line reads 'The recommended standard dosage is 15-25 mg /kg bodyweight (i.e. 2-3 tablets) two to three times daily' — the epistaxis-specific instruction sits at the lower end of that band. RENAL IMPAIRMENT: §4.2 gives a serum-creatinine-based reduction in oral dosage for mild to moderate renal insufficiency — see renalAdjustment; §4.3 contraindicates severe renal impairment outright. ELDERLY: §4.2, verbatim: 'No reduction in dosage is necessary unless there is evidence of renal insufficiency'. || THE PAGE'S TOPICAL INTRANASAL ROUTE REMAINS UNSOURCED: no UK SPC in this bundle licenses tranexamic acid for application to the nasal mucosa, so that route cannot be sourced from an SPC at all and would need a named guideline, recorded as off-label, before anything is published for it. The scope limit is stated inside the dose text so the published figure cannot be read as covering it.